Table 1 Clinical and metabolic features of included studies
Authors | Publication year | Country | Female/male | Study design | Follow-up period | Underling diseases | Sample size | Circulating MOTS-c (mean ± SD) | Age (y) | |
|---|---|---|---|---|---|---|---|---|---|---|
Mean | SD | |||||||||
Baylan, F. A. [19] | 2021 | Turkey | Not available | Case control | Not available | Normal | 14 | 211.4 | 119.7 | 50.4 ± 12.6 |
Obese (BMI > 28) | 18 | 190.4 | 115.4 | 56.4 ± 5.9 | ||||||
Du, C. [20] | 2018 | China | 17/40 | Case control | 2017 | Normal | 57 | 561.64 | 19.19 | 9.55 ± 0.33 |
13/27 | Obese (BMI = 24–28) | 40 | 472.61 | 22.8 | 10.37 ± 0.33 | |||||
Ramanjaneya, M. [21] | 2019 | Qatar | 35/33 | A cross-sectional study | Not available | Normal | 68 | 235.3 | 181.6 | 49.3 ± 10.6 |
18/13 | T2DM (HbA1c < 7%) | 31 | 186.3 | 125.6 | 54.7 ± 11.2 | |||||
37/56 | T2DM (HbA1c > 7%) | 93 | 157.7 | 136.6 | 57.2 ± 8.3 | |||||
Cataldo, L. R. [22] | 2018 | Chile | / | Case control | Not available | Normal males | 5 | 0.54 | 0.21 | 35.2 ± 8.5 |
Obese males (BMI > 28) | 5 | 0.49 | 0.11 | 37.8 ± 3.1 | ||||||
Normal females | 5 | 0.42 | 0.08 | 31.1 ± 5.0 | ||||||
Obese females (BMI > 28) | 5 | 0.55 | 0.19 | 34.0 ± 10.6 | ||||||
Jiang Fen [23] | 2020 | China | 28/15 | Case control | 2018–2019 | Normal | 43 | 72.36 | 19.78 | 53.36 ± 10.01 |
39/27 | T2DM | 66 | 12.88 | 11.4 | 44 ± 15.01 | |||||
Not available | Normal | 66 | 44.51 | 28.18 | Not available | |||||
Obese (BMI = 24–28) | 40 | 66.44 | 28.29 | Not available | ||||||
Obese (BMI > 28) | 43 | 54.49 | 35.68 | Not available | ||||||
Wojciechowska M [24] | 2021 | Poland | 9/9 | Case control | Not available | Normal | 18 | 427.66 | 148.93 | 30.09 ± 1.300 |
12/10 | Obese (BMI > 28) | 22 | 976 | 204.84 | 32.62 ± 1.243 | |||||
Wang Xiaogang [25] | 2022 | China | / | Case control | 2019–2021 | Normal | Not available | |||
12/10 | T2DM | 22 | 234.22 | 98.31 | 58.33 ± 4.23 | |||||